Organ-specific response to atezolizumab + bevacizumab combination therapy for unresectable hepatocellular carcinoma with extrahepatic metastases: a retrospective cohort study
Akihiro Dejima, Kuniaki Arai, Tomoyoshi Chiba, Hidenori Kido, Noboru Takata, Takeshi Terashima, Tatsuya Yamashita, Taro Yamashita · 2026
Read Organ-specific response to atezolizumab + bevacizumab combination therapy for unresectable hepatocellular carcinoma with extrahepatic metastases: a retrospective cohort study by Akihiro Dejima, Kuniaki Arai, Tomoyoshi Chiba, Hidenori Kido, Noboru Takata, Takeshi Terashima, Tatsuya Yamashita, Taro Yamashita (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13546581.txt.
Description
Akihiro Dejima and co-authors asked in 2026 whether a standard drug combination for advanced liver cancer works equally well in every organ the cancer has reached. The pairing of atezolizumab and bevacizumab is a first-line treatment, yet the liver's immune environment might blunt responses there. Records covered 42 patients treated at one Japanese hospital between 2020 and 2024 who had spread beyond the liver.
Overall, about a third of patients responded, and responses appeared in liver, lung, lymph nodes, and the abdominal lining, though not in the small bone and adrenal groups. Measured shrinkage and time to progression did not differ significantly between organs, but the groups were small. The authors describe the results as exploratory evidence of fairly even activity across sites.
Catalog record
| CREATOR | Akihiro Dejima, Kuniaki Arai, Tomoyoshi Chiba, Hidenori Kido, Noboru Takata, Takeshi Terashima, Tatsuya Yamashita, Taro Yamashita |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37299 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |